Tele: 561.316.3330
Breaking Medical Device News

Wednesday, October 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeRa Medical SystemsClinical Study Aims to Show DABRA Excimer Laser System Keeps Arteries Healthy...

Clinical Study Aims to Show DABRA Excimer Laser System Keeps Arteries Healthy Longer

The study will demonstrate the DABRA Excimer Laser System delivers effective, long-lasting results and a low reintervention rate for patients with peripheral artery disease. The study will gather data two years post-treatment in up to 2,500 patients.

Ra Medical Systems, Inc. announced they are conducting a study to demonstrate the DABRA Excimer Laser System delivers effective, long-lasting results and a low reintervention rate for patients with peripheral artery disease (PAD). The study will gather data two years post-treatment in up to 2,500 patients.

“Restenosis, or re-narrowing of an artery post-procedure, is a major problem for my patients,” said C.V. Ramana, MD, principal study investigator. “In my experience, DABRA has provided a highly effective treatment, with minimal vascular trauma, which I believe leads to lower rates of restenosis and longer lasting results,” Dr. Ramana practices at NAADI Healthcare in Oklahoma City, OK.

Restenosis is a challenge for physicians, patients, and the healthcare system, due to the additional cost and recovery time required with re-treating arterial blockages. Recent studies have reported the restenosis rate in peripheral interventions to be up to 70 percent at one-year post-procedure.1, 2

“In my practice, we are seeing very positive clinical outcomes using DABRA,” said Study Chairman Rajesh Dave, MD. “The goal of this study is to demonstrate the lasting lumen patency achieved with this exciting new technology.” Dr. Dave is Chairman of the Department of Cardiology, Geisinger Holy Spirit Hospital in Camp Hill, PA.

DABRA (Destruction of Arteriosclerotic Blockages by laser Radiation Ablation) is a novel, minimally invasive excimer laser photoablation system that non-thermally, photochemically ablates channels in vascular blockages. Unlike many mechanical, acoustic, or thermal treatments for peripheral artery disease that may damage the arterial wall, DABRA treats blockages with minimal vascular trauma.

“Our mission at Ra Medical Systems is to help physicians save patients’ limbs and lives,” said Dean Irwin, CEO. “We believe the clinical study will demonstrate that patients do not have to return to their doctor to be re-treated for the same blockage, which benefits that patient and the healthcare system as a whole.”

The study is named RESULTS (REvascularization RateS and Clinical OUtcomes with DABRA Laser: A Long-Term 2-year Study). It is a multi-site registry study, including up to 50 U.S. hospital or office-based lab sites and 2,500 patients with Rutherford Classification 2-6. Each patient will receive follow-up at six-month intervals for a total subject participation of two years.


References

1 https://www.sciencedirect.com/science/article/pii/S0890509617302625
2 https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.113.001811?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Luciana Borio MD is a respected physician with vast experience in advancing major regulatory and policy agendas for the United States.

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy